Trials / Completed
CompletedNCT02161952
Pirfenidone, an Antifibrotic and Antiinflammatory Drug
Pirfenidone, an Antifibrotic and Antiinflammatory Drug for Treatment of Patients With Cirrhosis Due to Hepatitis C Virus. Phase II/III Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- University of Guadalajara · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study was to assess whether two-year treatment with Pirfenidone influence necro-inflammation, fibrosis and steatosis in patients with chronic hepatitis C.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirfenidone | Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months. |
| DRUG | Matched equivalent placebo |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2006-08-01
- Completion
- 2007-08-01
- First posted
- 2014-06-12
- Last updated
- 2014-07-09
Source: ClinicalTrials.gov record NCT02161952. Inclusion in this directory is not an endorsement.